The Manufacturers Life Insurance Company Takes $27.11 Million Position in Moderna, Inc. $MRNA

Key Points

• The Manufacturers Life Insurance Company acquired 387,074 Moderna shares worth approximately $27.11 million, representing about 0.10% of the company. Institutional investors collectively own 75.33% of Moderna.
• Moderna received FDA approval for updated 2026–2027 COVID-19 vaccines and continues to build its oncology pipeline, with its personalized melanoma vaccine showing an approximately 49% reduction in recurrence in a late-stage study.
• The company plans to raise $2 billion through convertible senior notes to fund oncology investments and repay debt, but the financing raises concerns about potential dilution. Moderna remains unprofitable, and analysts maintain a consensus “Hold” rating with a $74.31 target price.

The Manufacturers Life Insurance Company acquired a new stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 387,074 shares of the company's stock, valued at approximately $27,107,000. The Manufacturers Life Insurance Company owned about 0.10% of Moderna at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Allied Private Wealth LLC purchased a new position in Moderna in the 2nd quarter worth about $30,000. Canton Hathaway LLC purchased a new stake in shares of Moderna during the 1st quarter valued at about $31,000. Frazier Financial Advisors LLC purchased a new stake in shares of Moderna during the 2nd quarter valued at about $45,000. Mowery & Schoenfeld Wealth Management LLC bought a new stake in shares of Moderna in the second quarter worth approximately $49,000. Finally, Assetmark Inc. grew its stake in shares of Moderna by 35.1% in the first quarter. Assetmark Inc. now owns 801 shares of the company's stock worth $41,000 after acquiring an additional 208 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: The FDA approved Moderna’s updated 2026–2027 Spikevax and mNEXSPIKE COVID-19 vaccines, which target the XFG subvariant. The approval supports Moderna’s ability to participate in the upcoming seasonal vaccination market, although Spikevax eligibility is focused on adults 65 and older and higher-risk people ages 6 months through 64. FDA approves updated COVID vaccines
• Positive Sentiment: Renewed attention on Moderna and Merck’s personalized cancer vaccine, intismeran, is supporting the company’s long-term oncology story. Reports indicate the therapy reduced melanoma recurrence by approximately 49% in a late-stage study, strengthening expectations that Moderna could diversify beyond its declining COVID-19 business. Personalized melanoma vaccine results
• Neutral Sentiment: Moderna announced plans to raise $2 billion through convertible senior notes due in 2032, with an option for purchasers to increase the deal to $2.3 billion. Proceeds may fund oncology investments and debt repayment, while a hedge overlay is intended to offset dilution up to a specified cap. Moderna convertible notes offering
• Negative Sentiment: Investors are reacting cautiously to the financing because convertible notes can create future share dilution and signal substantial funding needs. The offering comes while Moderna remains unprofitable, making the company’s elevated valuation more difficult to justify on current earnings and revenue. Moderna borrows $2 billion

Insider Buying and Selling at Moderna

In other news, insider Shannon Thyme Klinger sold 3,471 shares of the company's stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total value of $173,550.00. Following the completion of the sale, the insider directly owned 67,468 shares in the company, valued at $3,373,400. This represents a 4.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of the firm's stock in a transaction on Monday, June 15th. The stock was sold at an average price of $51.37, for a total value of $2,739,870.32. Following the completion of the transaction, the president directly owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. This represents a 3.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 10.80% of the company's stock.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $142.77 on Friday. The firm's 50 day moving average price is $75.62 and its 200-day moving average price is $59.17. Moderna, Inc. has a twelve month low of $22.28 and a twelve month high of $176.66. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $57.00 billion, a PE ratio of -17.87 and a beta of 0.91.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. During the same quarter last year, the firm posted ($2.13) earnings per share. The firm's revenue was up 2.1% compared to the same quarter last year. Equities research analysts expect that Moderna, Inc. will post -6.18 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on MRNA. UBS Group increased their price objective on shares of Moderna from $50.00 to $150.00 and gave the company a "neutral" rating in a research report on Thursday, August 20th. Bank of America raised shares of Moderna from an "underperform" rating to a "neutral" rating in a research report on Wednesday, August 19th. Brookline Capital Markets reiterated a "buy" rating on shares of Moderna in a research note on Wednesday, August 19th. Citigroup increased their price target on Moderna from $41.00 to $60.00 and gave the company a "neutral" rating in a report on Monday, August 3rd. Finally, Jefferies Financial Group restated a "hold" rating on shares of Moderna in a research note on Wednesday, August 19th. Four equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $74.31.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source